Last reviewed · How we verify
Chemo-radiotherapy alone
Chemo-radiotherapy combines chemotherapy drugs with targeted radiation to kill cancer cells through dual cytotoxic mechanisms.
Chemo-radiotherapy combines chemotherapy drugs with targeted radiation to kill cancer cells through dual cytotoxic mechanisms. Used for Locally advanced solid tumors (specific indication under investigation in phase 3 trial).
At a glance
| Generic name | Chemo-radiotherapy alone |
|---|---|
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This combined modality approach uses chemotherapy agents to damage cancer cell DNA and inhibit proliferation while simultaneously delivering high-dose ionizing radiation to the tumor site. The chemotherapy can act as a radiosensitizer, enhancing the effectiveness of radiation therapy. This combination is designed to achieve better local control and systemic disease management than either modality alone.
Approved indications
- Locally advanced solid tumors (specific indication under investigation in phase 3 trial)
Common side effects
- Hematologic toxicity (anemia, leukopenia, thrombocytopenia)
- Mucositis
- Nausea and vomiting
- Fatigue
- Radiation dermatitis
- Esophagitis
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones (PHASE2)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas (PHASE3)
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemo-radiotherapy alone CI brief — competitive landscape report
- Chemo-radiotherapy alone updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI